Cargando…

Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis

BACKGROUND: Cardiomyocytes differentiated from human pluripotent stem cells can serve as an unexhausted source for a cellular cardiac disease model. Although small molecule–mediated cardiomyocyte differentiation methods have been established, the differentiation efficiency is relatively unsatisfacto...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Xiao‐Xu, Liu, Yang, Zhang, Yi‐Fan, Guan, Ya‐Na, Jia, Qian‐Qian, Wang, Chen, Liang, He, Li, Yong‐Qin, Yang, Huang‐Tian, Qin, Yong‐Wen, Huang, Shuang, Zhao, Xian‐Xian, Jing, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721819/
https://www.ncbi.nlm.nih.gov/pubmed/28971953
http://dx.doi.org/10.1161/JAHA.116.005295
_version_ 1783284888769658880
author Qiu, Xiao‐Xu
Liu, Yang
Zhang, Yi‐Fan
Guan, Ya‐Na
Jia, Qian‐Qian
Wang, Chen
Liang, He
Li, Yong‐Qin
Yang, Huang‐Tian
Qin, Yong‐Wen
Huang, Shuang
Zhao, Xian‐Xian
Jing, Qing
author_facet Qiu, Xiao‐Xu
Liu, Yang
Zhang, Yi‐Fan
Guan, Ya‐Na
Jia, Qian‐Qian
Wang, Chen
Liang, He
Li, Yong‐Qin
Yang, Huang‐Tian
Qin, Yong‐Wen
Huang, Shuang
Zhao, Xian‐Xian
Jing, Qing
author_sort Qiu, Xiao‐Xu
collection PubMed
description BACKGROUND: Cardiomyocytes differentiated from human pluripotent stem cells can serve as an unexhausted source for a cellular cardiac disease model. Although small molecule–mediated cardiomyocyte differentiation methods have been established, the differentiation efficiency is relatively unsatisfactory in multiple lines due to line‐to‐line variation. Additionally, hurdles including line‐specific low expression of endogenous growth factors and the high apoptotic tendency of human pluripotent stem cells also need to be overcome to establish robust and efficient cardiomyocyte differentiation. METHODS AND RESULTS: We used the H9–human cardiac troponin T–eGFP reporter cell line to screen for small molecules that promote cardiac differentiation in a monolayer‐based and growth factor–free differentiation model. We found that collaterally treating human pluripotent stem cells with rapamycin and CHIR99021 during the initial stage was essential for efficient and reliable cardiomyocyte differentiation. Moreover, this method maintained consistency in efficiency across different human embryonic stem cell and human induced pluripotent stem cell lines without specifically optimizing multiple parameters (the efficiency in H7, H9, and UQ1 human induced pluripotent stem cells is 98.3%, 93.3%, and 90.6%, respectively). This combination also increased the yield of cardiomyocytes (1:24) and at the same time reduced medium consumption by about 50% when compared with the previous protocols. Further analysis indicated that inhibition of the mammalian target of rapamycin allows efficient cardiomyocyte differentiation through overcoming p53‐dependent apoptosis of human pluripotent stem cells during high‐density monolayer culture via blunting p53 translation and mitochondrial reactive oxygen species production. CONCLUSIONS: We have demonstrated that mammalian target of rapamycin exerts a stage‐specific and multifaceted regulation over cardiac differentiation and provides an optimized approach for generating large numbers of functional cardiomyocytes for disease modeling and in vitro drug screening.
format Online
Article
Text
id pubmed-5721819
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57218192017-12-12 Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis Qiu, Xiao‐Xu Liu, Yang Zhang, Yi‐Fan Guan, Ya‐Na Jia, Qian‐Qian Wang, Chen Liang, He Li, Yong‐Qin Yang, Huang‐Tian Qin, Yong‐Wen Huang, Shuang Zhao, Xian‐Xian Jing, Qing J Am Heart Assoc Original Research BACKGROUND: Cardiomyocytes differentiated from human pluripotent stem cells can serve as an unexhausted source for a cellular cardiac disease model. Although small molecule–mediated cardiomyocyte differentiation methods have been established, the differentiation efficiency is relatively unsatisfactory in multiple lines due to line‐to‐line variation. Additionally, hurdles including line‐specific low expression of endogenous growth factors and the high apoptotic tendency of human pluripotent stem cells also need to be overcome to establish robust and efficient cardiomyocyte differentiation. METHODS AND RESULTS: We used the H9–human cardiac troponin T–eGFP reporter cell line to screen for small molecules that promote cardiac differentiation in a monolayer‐based and growth factor–free differentiation model. We found that collaterally treating human pluripotent stem cells with rapamycin and CHIR99021 during the initial stage was essential for efficient and reliable cardiomyocyte differentiation. Moreover, this method maintained consistency in efficiency across different human embryonic stem cell and human induced pluripotent stem cell lines without specifically optimizing multiple parameters (the efficiency in H7, H9, and UQ1 human induced pluripotent stem cells is 98.3%, 93.3%, and 90.6%, respectively). This combination also increased the yield of cardiomyocytes (1:24) and at the same time reduced medium consumption by about 50% when compared with the previous protocols. Further analysis indicated that inhibition of the mammalian target of rapamycin allows efficient cardiomyocyte differentiation through overcoming p53‐dependent apoptosis of human pluripotent stem cells during high‐density monolayer culture via blunting p53 translation and mitochondrial reactive oxygen species production. CONCLUSIONS: We have demonstrated that mammalian target of rapamycin exerts a stage‐specific and multifaceted regulation over cardiac differentiation and provides an optimized approach for generating large numbers of functional cardiomyocytes for disease modeling and in vitro drug screening. John Wiley and Sons Inc. 2017-10-02 /pmc/articles/PMC5721819/ /pubmed/28971953 http://dx.doi.org/10.1161/JAHA.116.005295 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Qiu, Xiao‐Xu
Liu, Yang
Zhang, Yi‐Fan
Guan, Ya‐Na
Jia, Qian‐Qian
Wang, Chen
Liang, He
Li, Yong‐Qin
Yang, Huang‐Tian
Qin, Yong‐Wen
Huang, Shuang
Zhao, Xian‐Xian
Jing, Qing
Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
title Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
title_full Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
title_fullStr Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
title_full_unstemmed Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
title_short Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53‐Dependent Apoptosis
title_sort rapamycin and chir99021 coordinate robust cardiomyocyte differentiation from human pluripotent stem cells via reducing p53‐dependent apoptosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721819/
https://www.ncbi.nlm.nih.gov/pubmed/28971953
http://dx.doi.org/10.1161/JAHA.116.005295
work_keys_str_mv AT qiuxiaoxu rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT liuyang rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT zhangyifan rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT guanyana rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT jiaqianqian rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT wangchen rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT lianghe rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT liyongqin rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT yanghuangtian rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT qinyongwen rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT huangshuang rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT zhaoxianxian rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis
AT jingqing rapamycinandchir99021coordinaterobustcardiomyocytedifferentiationfromhumanpluripotentstemcellsviareducingp53dependentapoptosis